Building a Global Database Linking Genes and Health Records in Serious Mental Illness

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with major depression, bipolar disorder, schizophrenia, or dementia or memory problems, who have an electronic health record. It builds a research database from health records and samples.

Age

18 years and older (up to 110 years)

Sex

All sexes can join.

Disease stage

Mental health group: a diagnosis or treatment or referral for major depression, bipolar disorder or schizophrenia. Dementia group: a diagnosis of dementia, mild cognitive impairment or subjective cognitive impairment, or a memory clinic referral.

Main reasons for not taking part

• Mental health group: people who cannot give consent
• Dementia group: people who cannot understand spoken or written English
• People with intellectual disability (dementia group)
• Dementia due to CJD, Huntington's, HIV, alcohol or traumatic brain injury
• Dementia group: not able to complete a cognitive test (MoCA or SLUMS)

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 110 years old?YesNo

What the trial wants to find out

This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved treatments. The investigators will achieve aims by gathering information and biological samples from over 50,000 research participants and then linking this information with participants' electronic health records, genetic and other potential markers of mental illnesses (called biomarkers, derived from biological samples). The investigators will use this resource to analyse how potential risk factors - genetic, other biological and non-biological (related to the participants' life circumstances) - influence participants' experiences, symptoms, and outcomes (both mental and physical health). The investigators will also use advanced analysis to assess whether there may be better ways of grouping together and understanding the experiences of those with severe mental illnesses and dementias. Given the value and importance of this resource for advancing mental health research, the investigators will also make the data available to other researchers to pursue these broad research aims.

The 3 groups in the trial

• Cohort 1

  40,000 participants with linked EHR and baseline assessments will provide a DNA sample only, via saliva or blood. This cohort will comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 13,300 patients in each group).

  Treatment: Not applicable- observational study

• Cohort 2

  9,000 participants with linked EHR and baseline assessments patients will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood. This cohort will also comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 3000 patients in each group).

  Treatment: Not applicable- observational study

• Cohort 3

  1000 participants with Dementia who have linked EHR and assessments will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood.

  Treatment: Not applicable- observational study